---
title: "Emmaus Life Sciences delays 2024 annual report"
url: "https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-04-01"
section: "Distress"
tickers: "OTC:EMMA"
source: "https://www.sec.gov/Archives/edgar/data/822370/000121390025027099/ea0236353-nt10k_emmaus.htm"
summary: "The company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 mill"
---

By the aibio.space news desk.

Sources

- [Emmaus Life Sciences, Inc. NT 10-K (2025-04-01)](https://www.sec.gov/Archives/edgar/data/822370/000121390025027099/ea0236353-nt10k_emmaus.htm)

[EMMA](https://aibio.space/companies/emmaus-life-sciences/)

2025-04-01

# Emmaus Life Sciences delays 2024 annual report, sees revenue down more than $12 million

Tickers [EMMA](https://aibio.space/companies/emmaus-life-sciences/)

The company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024.

## Key facts

- **Company**: Emmaus Life Sciences, Inc. (OTC: EMMA)

- **News type**: Distress

- **Primary source**: [Emmaus Life Sciences, Inc. NT 10-K (2025-04-01)](https://www.sec.gov/Archives/edgar/data/822370/000121390025027099/ea0236353-nt10k_emmaus.htm)

*The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Emmaus Life Sciences, Inc. said it will not file its annual report on Form 10-K for the year ended December 31, 2024 by the due date and gave preliminary figures for the year.

In a [Form 12b-25](https://www.sec.gov/Archives/edgar/data/822370/000121390025027099/ea0236353-nt10k_emmaus.htm) notice of late filing, the Torrance, California company said it needs more time to provide information for the first audit of its annual financial statements by its registered independent accounting firm. Emmaus retained that firm in September 2024. It expects to file the 10-K on or before the 15th calendar day after the due date.

The company also estimated that net revenues for 2024 will decline by more than $12 million, or more than 40%, compared with 2023. It said the decline was due primarily to a lack of finished goods inventory for much of the first half of 2024.

Emmaus expects the revenue drop to be partly offset by a cut in operating expenses of more than $7 million, or about 30%. It estimates a loss from operations of approximately $1.9 million for 2024, compared with income from operations of approximately $3.5 million in 2023.

The company estimated a net loss of approximately $0.10 per share in 2024, against a net loss of $0.07 per share in 2023.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

EMMA

Emmaus Life Sciences, Inc.

OTC · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Emmaus Life Sciences delays 2024 annual report", 2025-04-01, https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/